{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"PVAOGZXUOOHSMN-UHFFFAOYSA-N","prefName":"CB-86","symbol":"CB-86","iupacName":"N-cyclopropyl-8-[3-hydroxy-5-(2-methyloctan-2-yl)phenoxy]octanamide","aliases":["CB-86","NS00017572"],"cas":null,"pubchemCid":"42625202","chebiId":null,"smiles":"CCCCCCC(C)(C)C1=CC(=CC(=C1)OCCCCCCCC(=O)NC2CC2)O","molecularFormula":"C26H43NO3","molecularWeight":417.6,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/42625202"}},"classification":{"family":"ecs_tool","familyLabel":"ECS modulator (research)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (research tool)","summaryFr":"No biosynthetic pathway: the molecule is obtained by chemical synthesis. Class of synthesis: an ether of a resorcinol bearing a 2-methyloctan-2-yl group, linked to an N-cyclopropyl amide by a carbon chain.","originNote":"Synthetic molecule. No plant source is documented for this compound in the sources consulted. It belongs to the series of resorcinol-anandamide hybrids, designed from the pharmacophoric requirements of THC and anandamide.","discovered":""},"pharmacology":{"summaryFr":"CB-86 is a synthetic resorcinol-anandamide hybrid, described in 2009 by Brizzi et al. in the Journal of Medicinal Chemistry. The published measurements report an inhibition constant of 5.6 nM at CB1 and 7.9 nM at CB2, on human receptors expressed in COS cells. The summary of the study reports in vivo antinociceptive activity for the series. No human data have been found, and its documented use is research.","receptorSummaryFr":"CB1 and CB2 receptor ligand. The 2009 study reports an inhibition constant (Ki) of 5.6 nM at CB1 and 7.9 nM at CB2, measured by radioligand displacement on human receptors expressed in COS cells (Brizzi et al., 2009). The summary consulted links higher affinity to the presence of a 2-methyloctan-2-yl group at position 5, as is the case here. It does not qualify the type of activity (agonist or antagonist): no functional data were found in the sources consulted.","binding":[{"target":"CB1","efficacy":"modulator","relativeActivity":88,"reported":"Ki 5,6 nM (Brizzi et coll., 2009)","confidence":"medium"},{"target":"CB2","efficacy":"modulator","relativeActivity":85,"reported":"Ki 7,9 nM (Brizzi et coll., 2009)","confidence":"medium"}],"references":[{"label":"Brizzi et coll., hybrides résorcinol-anandamide comme ligands puissants des récepteurs cannabinoïdes, J Med Chem 2009","pmid":"19331413","doi":"10.1021/jm8016255","url":"https://pubmed.ncbi.nlm.nih.gov/19331413/"},{"label":"ChEMBL, molécule CHEMBL490648 (affinités CB1 et CB2, document CHEMBL1153817)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL490648/"},{"label":"PubChem, notice du composé CB-86 (CID 42625202)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/42625202"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":8},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":2},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":3},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":2},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":2}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised control measure at European Union level was found for this molecule in the sources consulted: any control falls, where it exists, under the national law of each Member State.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"CB-86 is not named in any annex of the decree of 22 February 1990, nor in the ANSM consolidated list (update of 16 February 2026). It is not a tetrahydrocannabinol, nor an ester, ether or salt of one (the 'Tetrahydrocannabinols' entry of the list), and it has no benzo[c]chromene core (clause of 22 May 2024). It has no cyclohexylphenol core (2-(3-hydroxycyclohexyl)phenol), no indole or indazole ring and no naphthoyl group, so it cannot be attached to any of the generic family definitions in the list. It is therefore unscheduled in France. This status is not an authorisation.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Brizzi et coll., hybrides résorcinol-anandamide comme ligands puissants des récepteurs cannabinoïdes, J Med Chem 2009","pmid":"19331413","doi":"10.1021/jm8016255","url":"https://pubmed.ncbi.nlm.nih.gov/19331413/"},{"label":"ChEMBL, molécule CHEMBL490648 (affinités CB1 et CB2, document CHEMBL1153817)","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL490648/"},{"label":"PubChem, notice du composé CB-86 (CID 42625202)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/42625202"},{"label":"ANSM, liste consolidée des substances classées comme stupéfiants (mise à jour du 16 février 2026)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (conventions de 1961 et 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"cb-86","url":"https://en.phytogrammes.com/wiki/cb-86","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}